Published in Cancer Res on August 15, 2007
BIN1 localizes the L-type calcium channel to cardiac T-tubules. PLoS Biol (2010) 2.34
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm (2012) 1.49
Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One (2012) 1.48
Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci (2015) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta (2008) 1.12
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
DNA methylation age of blood predicts future onset of lung cancer in the women's health initiative. Aging (Albany NY) (2015) 1.03
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology (2013) 0.94
Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation. Cell Death Differ (2014) 0.92
Bin1 SRC homology 3 domain acts as a scaffold for myofiber sarcomere assembly. J Biol Chem (2009) 0.90
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther (2011) 0.89
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle (2012) 0.88
Multilayered regulation of cardiac ion channels. Biochim Biophys Acta (2012) 0.87
Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med (2012) 0.87
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders. Oncotarget (2011) 0.82
Frequent alteration of the tumor suppressor gene APC in sporadic canine colorectal tumors. PLoS One (2012) 0.81
BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia (2015) 0.78
Bin1: a new player in IBD barrier dysfunction. Dig Dis Sci (2012) 0.76
Hyper-Methylated Loci Persisting from Sessile Serrated Polyps to Serrated Cancers. Int J Mol Sci (2017) 0.75
Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? Dig Dis Sci (2016) 0.75
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol (2007) 3.59
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Proton-coupled electron transfer. Chem Rev (2007) 3.01
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol (2013) 2.69
Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res (2005) 2.67
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res (2004) 1.84
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
L1 recombination-associated deletions generate human genomic variation. Proc Natl Acad Sci U S A (2008) 1.79
Chemical approaches to artificial photosynthesis. 2. Inorg Chem (2005) 1.78
Proton-coupled electron transfer. Chem Rev (2012) 1.75
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res (2010) 1.71
Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis (2006) 1.64
Alu recombination-mediated structural deletions in the chimpanzee genome. PLoS Genet (2007) 1.59
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
One site is enough. Catalytic water oxidation by [Ru(tpy)(bpm)(OH2)]2+ and [Ru(tpy)(bpz)(OH2)]2+. J Am Chem Soc (2008) 1.55
Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition. Mol Cell (2005) 1.53
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res (2004) 1.51
Molecular basis of gastric cancer development and progression. Gastric Cancer (2004) 1.49
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Mobile DNA in Old World monkeys: a glimpse through the rhesus macaque genome. Science (2007) 1.47
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res (2011) 1.45
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer (2014) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer (2007) 1.34
Multiple mixed-valence behavior in trans,trans-[(tpy)(Cl)2Os(III)(mu-1,3-N3)Os(III)(Cl)2(tpy)]+. An azido bridge from the reaction between trans-[Os(VI)(tpy)(Cl)2(N)]+ and NH3. J Am Chem Soc (2003) 1.33
Chromosomal inversions between human and chimpanzee lineages caused by retrotransposons. PLoS One (2008) 1.32
Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.30
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Making oxygen with ruthenium complexes. Acc Chem Res (2009) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer (2004) 1.24
Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res (2005) 1.24
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res (2013) 1.21
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Electrocatalytic oxidation of tyrosine by parallel rate-limiting proton transfer and multisite electron-proton transfer. J Am Chem Soc (2006) 1.17
Raphe GABAergic neurons mediate the acquisition of avoidance after social defeat. J Neurosci (2013) 1.16
Mechanisms of water oxidation from the blue dimer to photosystem II. Inorg Chem (2008) 1.16
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
The role of free energy change in coupled electron-proton transfer. J Am Chem Soc (2007) 1.16
Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des (2012) 1.15
Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res (2011) 1.14
Chemical approaches to artificial photosynthesis. Proc Natl Acad Sci U S A (2012) 1.12
Switching-on quantum size effects in silicon nanocrystals. Adv Mater (2014) 1.12
BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta (2008) 1.12
KLF4α up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology (2010) 1.11
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Nanostructured tin catalysts for selective electrochemical reduction of carbon dioxide to formate. J Am Chem Soc (2014) 1.11
Dynein-mediated apical localization of crumbs transcripts is required for Crumbs activity in epithelial polarity. J Cell Biol (2008) 1.10
RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res (2006) 1.10
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis (2004) 1.10
Concerted O atom-proton transfer in the O-O bond forming step in water oxidation. Proc Natl Acad Sci U S A (2010) 1.09
HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci (2012) 1.08
Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res (2007) 1.08
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Single-site, catalytic water oxidation on oxide surfaces. J Am Chem Soc (2009) 1.05
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets (2005) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Energy transfer dynamics in metal-organic frameworks. J Am Chem Soc (2010) 1.01
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Mechanism of water oxidation by single-site ruthenium complex catalysts. J Am Chem Soc (2010) 1.00
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res (2003) 1.00
Suppression of ClC-3 channel expression reduces migration of nasopharyngeal carcinoma cells. Biochem Pharmacol (2008) 1.00